...
The Good Laboratory is focused on understanding the mechanisms that regulate blood vessel function and inflammation and their contribution to the development of neurological diseases. Alzheimer’s Disease (AD) and ischemic stroke are both in the top 10 leading causes of mortality in the US, however, therapeutics are severely lacking to improve outcomes in these patients. CBF dysregulation, blood-brain barrier (BBB) dysfunction and neuroinflammation are key features observed chronically in Alzheimer’s Disease patients and acutely in ischemic stroke patients. A gap in our knowledge, and an area with high potential for pharmacological intervention, is understanding vascular-mediated mechanisms that influence ischemic stroke outcome, such as recovery of cerebral blood flow (CBF) and inflammatory responses, and progression of Alzheimer’s disease.